Forest Laboratories, Almirall announce availability of anticholinergic agent in US
The FDA approved long-acting anticholinergic was indicated for the maintenance treatment of bronchospasm coupled with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. When administered two times
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.